Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gesves – page 53

942 clinical trials in Gesves, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gesves at a glance
942
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

942 trials in Gesves

Open in trial search

Migraine

Not recruiting

Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Crohn's disease

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Crohn's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ciprofloxacin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Glioma

Not recruiting

Study of Abemaciclib and Temozolomide for Children and Young Adults with Newly Diagnosed High-Grade Glioma After Radiotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Study on the Safety and Effects of Delandistrogene Moxeparvovec in Children Under 4 with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Delandistrogene Moxeparvovec
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm malignant

Not recruiting

Study on the Safety of Avelumab, Lorlatinib, and Axitinib for Cancer Patients Continuing from Previous Trials

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:Pfizer Inc.

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Anaemia

Not recruiting

Study on the Effectiveness and Safety of Mitapivat for Patients with Sickle Cell Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Neoplasm+2

Not recruiting

Study of ELVN-002 with Trastuzumab and Chemotherapy for Patients with Advanced HER2+ Solid Tumors, Colorectal Cancer, and Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Enliven Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gesves

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on chronic rhinosinusitis treatment, specifically targeting patients with nasal polyps. Clinical investigations are evaluating novel therapeutic approaches using monoclonal antibodies to improve patient outcomes.

  • Nasal Polyp Management
  • Anti-IL-33 Therapy
  • Rhinosinusitis Treatment

The trials aim to assess new therapeutic options for patients with inadequately controlled symptoms, focusing on reducing polyp size and alleviating nasal congestion.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.